GEMM GEP-NENs Version 3
Research type
Research Study
Full title
A comprehensive multiomic examination of the genetic, epigenetic, microbial and metabolomic landscape of gastro-enteropancreatic neuroendocrine neoplasms.
IRAS ID
329309
Contact name
Krista Rombouts
Contact email
Sponsor organisation
University College London
Clinicaltrials.gov Identifier
Z6364106/2024/01/35, UCL Project Data Protection Registration
Duration of Study in the UK
3 years, 0 months, 1 days
Research summary
This study aims to perform an in-depth genetic (DNA and RNA i.e. human protein building blocks) analysis of a large number of human cancer tissue samples from patients with a rare form of gut cancer (gastroenteropancreatic neuroendocrine neoplasms). With the information from laboratory experiments, the study aims to provide a better understanding of the factors that cause the cancer to occur and spread.
In healthy people, upto 95% of the total body's serotonin (a hormone with several actions) is produced by the microbiome (communities of normal micro-organisms that live in the gut), however the interactions of the microbiome, the metabolites (products of hormone breakdown- the metabolome) and GEP-NENS have not been fully investigated. In other tumour types, individuals' microbiome and metabolome may impact response to treatment and prognosis.
The primary objective of this study is to develop a more comprehensive understanding of the genetic (building blocks) and epigenetic (scaffold lining the building blocks) landscape of this tumour type and identify the role the microbiome and metabolome plays in this.
This will be used to develop new medicines different from the chemotherapy available for this tumour type; they will be more personalised, could reduce toxicity, maintain and improve quality of life and prolong lifespan.
REC name
East Midlands - Nottingham 1 Research Ethics Committee
REC reference
24/EM/0035
Date of REC Opinion
20 Feb 2024
REC opinion
Further Information Favourable Opinion